Press Releases April 15, 2026 08:00 PM

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Emergent BioSolutions announces Q1 2026 financial results conference call scheduled for April 30, 2026.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
EBS

Emergent BioSolutions, a public health-focused biopharmaceutical company, will report its first quarter 2026 financial results on April 30, 2026. The company will host a live webcast conference call accessible via its investor relations website, providing detailed financial performance and business updates.

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026
EBS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q1 2026 financial results to be announced on April 30, 2026.
  • Conference call accessible via webcast and telephone for investors and media.
  • Company specializes in biopharmaceutical solutions addressing public health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.

GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026.

Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

A replay of the call can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
[email protected]  

Media Contact:
Assal Hellmer
Vice President, Communications
[email protected]


Risks

  • Financial performance fluctuations impacting stock price and investor confidence.
  • Market and regulatory risks in the biopharmaceutical and public health sectors.
  • Potential operational challenges related to product development and public health demand.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026